

Title (en)

TREATMENT OF AGE-RELATED DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS

Title (de)

BEHANDLUNG VON ALTERSBEDINGTER DEGENERATION UND ANDEREN AUGENKRANKHEITEN MIT APOLIPOPROTEINMIMETIKA

Title (fr)

TRAITEMENT DE LA DÉGÉNÉRÉSCENCE LIÉE À L'ÂGE ET D'AUTRES MALADIES OCULAIRES AVEC DES MIMÉTIQUES D'APOLIPOPROTÉINE

Publication

EP 3554531 A1 20191023 (EN)

Application

EP 17703587 A 20170124

Priority

US 2017014754 W 20170124

Abstract (en)

[origin: WO2018139991A1] The present disclosure provides apolipoprotein (apo) mimetics useful for the treatment of age- related macular degeneration (AMD) and other eye disorders. The apo mimetics can be peptides/polypeptides that mimic, e.g., the lipid-clearing action of apolipoproteins such as apoA-I and apoE. The apo mimetics can exert other beneficial effects, such as reduction of inflammation, oxidative stress and neovascularization. The apo mimetics can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (GA) (including non-central GA and central GA) and neovascularization (NV) (including types 1, 2 and 3 NV). The apo mimetics can be used alone or in conjunction with other therapeutic agents, such as a complement: inhibitor and/or an anti-angiogenic agent, to treat AMD, including atrophic AMD and neovascular AMD, and other eye disorders.

IPC 8 full level

A61K 38/17 (2006.01); **A61P 27/02** (2006.01)

CPC (source: EP KR)

A61K 9/0019 (2013.01 - KR); **A61K 9/0048** (2013.01 - KR); **A61K 38/17** (2013.01 - EP KR); **A61K 45/06** (2013.01 - KR);
A61P 27/02 (2017.12 - EP KR); **A61K 2039/505** (2013.01 - KR); **A61K 2039/54** (2013.01 - KR); **A61K 2039/545** (2013.01 - KR)

Citation (search report)

See references of WO 2018139991A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2018139991 A1 20180802; CN 110545836 A 20191206; EP 3554531 A1 20191023; JP 2020514407 A 20200521;
KR 20190124704 A 20191105

DOCDB simple family (application)

US 2017014754 W 20170124; CN 201780087274 A 20170124; EP 17703587 A 20170124; JP 2019560039 A 20170124;
KR 20197021355 A 20170124